Our discovery platform enables us to develop fully human therapeutic antibodies for the treatment of immune-related diseases.
Therapies using monoclonal antibodies have proven to be effective in several inflammatory and immune diseases. A common approach is to use antibodies to target cytokines, receptors, and other signalling molecules.
We are determined to exploit the strength of our antibody discovery platform to deliver a new generation of therapeutic antibodies that tackle immune disorders, which continue to represent a high level of unmet clinical need.
Among Kymab’s projects is KY1005, an antibody targeting OX40L. We have selected this target because it high up in the signalling cascade, and by interfering with OX40 signalling we suppress multiple downstream cytokines simultaneously.
KY1005 is being developed for the treatment of autoimmune disease by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells.
We announced positive data in our Phase 1 trial of our fully human monoclonal antibody KY1005. The results from the Phase 1 study demonstrated that KY1005 had a favourable safety profile and was well tolerated. In addition, KY1005 was shown to block T cell-driven inflammation in the skin. The study was a single and multiple ascending- dose, placebo-controlled, double-blind, Phase 1 study in 64 healthy volunteers.
KY1005 efficacy is now being assessed for the treatment of severe-to moderate Atopic Dermatitis in a Phase 2b study. Additional plans include the testing of KY1005 in other immune-mediated diseases, such as Graft-versus- Host Disease (GvHD).